{"schema_version":"secwatch.filing_event.v1","accession":"0001682852-26-000147","form_type":"8-K","ticker":"MRNA","cik":"0001682852","company_name":"Moderna, Inc.","filed_at":"2026-07-31T11:03:47+00:00","discovered_at":"2026-07-31T11:05:00.339535+00:00","generated_at":"2026-07-31T11:05:15.331381+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Moderna Q2 net loss $(0.8)B, EPS $(1.97); norovirus vaccine misses interim endpoint","bullets":["Q2 revenue $145M (flat YoY); GAAP net loss $(0.8)B, EPS $(1.97) vs $(2.13) in Q2 2025.","2026 guidance: targeting up to 10% revenue growth; year-end cash improved to $4.7-5.2B; R&D expense lowered to ~$2.9B.","Norovirus vaccine mRNA-1403 failed early success criteria at Phase 3 interim; enrolling additional cohort.","mFLUSIVA (flu vaccine) PDUFA date Aug 5, 2026; potential fifth approved product.","Appointed Ester Banque as CCO and Michael McDonnell to Board."],"urls":{"canonical":"https://secwatch.observer/filing/0001682852-26-000147","json":"https://secwatch.observer/filing/0001682852-26-000147.json","markdown":"https://secwatch.observer/filing/0001682852-26-000147.md","text":"https://secwatch.observer/filing/0001682852-26-000147.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000147/0001682852-26-000147-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000147/mrna-20260731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-31T11:05:15.331381+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}